Circulating hematopoietic stem cells, endothelial progenitor cells and cancer stem cells in hepatocellular carcinoma patients: contribution to diagnosis and prognosis

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.
   PubMed Web of Science ®Google Scholar
• Hetta HF, Zahran AM, Mansor SG, et al. Frequency and Implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. J Med Virol. 2019;91:1319.
   PubMed Web of Science ®Google Scholar
• Zahran AM, Abdel-Meguid MM, Ashmawy AM, et al. Frequency and implications of natural killer and natural killer T cells in hepatocellular carcinoma. Egypt J Immunol. 2018;25:45–52.
   PubMedGoogle Scholar
• Chaturvedi VK, Singh A, Dubey SK, et al. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma. Microb Pathog. 2019;128:184–194.
   PubMed Web of Science ®Google Scholar
• Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001;234:63–70.
   PubMed Web of Science ®Google Scholar
• T P Poon R, Ng K, Lam C-M, et al. Effectiveness of radiofrequency ablation for hepatocellular carcinomas larger than 3 cm in diameter. Arch Surg. 2004;139:281–287.
   PubMedGoogle Scholar
• Abd Ellah NH, Tawfeek HM, John J, et al. Nanomedicine as a future therapeutic approach for hepatitis C virus. Nanomedicine. 2019;14:1471–1491.
   PubMed Web of Science ®Google Scholar
• Hassan EA, Ahmed EH, Nafee AM, et al. Regulatory T cells, IL10 and IL6 in HCV related hepatocellular carcinoma after transarterial chemoembolization (TACE). Egypt J Immunol. 2019;26:69–78.
   PubMedGoogle Scholar
• Ng KT, Poon R, Lo C-M, et al. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg. 2008;12:183–191.
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol. 2014;184:574–583.
   PubMed Web of Science ®Google Scholar
• Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: where are we? World J Exp Med. 2016;6:21–36.
   PubMedGoogle Scholar
• Hetta HF, Elkady A, Tohamy TA, et al. Regulatory B cells: key players in hepatocellular carcinoma progression. Gastroenterol Hepatol Open Access. 2016;5:00136.
   Google Scholar
• Ho JW, Pang RW, Lau C, et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology. 2006;44:836–843.
   PubMed Web of Science ®Google Scholar
• Ding Y-t, Kumar S, Yu D-C. The role of endothelial progenitor cells in tumour vasculogenesis. Pathobiology. 2008;75:265–273.
   PubMed Web of Science ®Google Scholar
• Yang ZF, Poon RT. Vascular changes in hepatocellular carcinoma. Anat Rec (Hoboken). 2008;291:721–734.
   PubMedGoogle Scholar
• Chen C-H, Li C, Tung W-C, et al. Levels and values of circulating endothelial progenitor cells, soluble angiogenic factors, and mononuclear cell apoptosis in liver cirrhosis patients. J Biomed Sci. 2012;19:66.
   PubMed Web of Science ®Google Scholar
• Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest. 2000;105:17–19.
   PubMed Web of Science ®Google Scholar
• Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194–1201.
   PubMed Web of Science ®Google Scholar
• Yu D, Sun X, Qiu Y, et al. Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clin Cancer Res. 2007;13:3814–3824.
   PubMed Web of Science ®Google Scholar
• Sieghart W, Fellner S, Reiberger T, et al. Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma. Dig Liver Dis. 2009;41:902–906.
   PubMedGoogle Scholar
• Yu D-C, Chen J, Sun X-t, et al. Mechanism of endothelial progenitor cell recruitment into neo-vessels in adjacent non-tumor tissues in hepatocellular carcinoma. BMC Cancer. 2010;10:435.
   PubMed Web of Science ®Google Scholar
• Zhu H, Shao Q, Sun X, et al. The mobilization, recruitment and contribution of bone marrow-derived endothelial progenitor cells to the tumor neovascularization occur at an early stage and throughout the entire process of hepatocellular carcinoma growth. Oncol Rep. 2012;28:1217–1224.
   PubMed Web of Science ®Google Scholar
• Gadelhak NA, Gadelhak SA, El Morsi DA, et al. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma. Hepatogastroenterology. 2009;56:1417–1424.
   PubMedGoogle Scholar
• Fürstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer. 2006;94:524–531.
   PubMed Web of Science ®Google Scholar
• Mellick A, Plummer P, Nolan D, et al. Using the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth. Cancer Res. 2010;70:7273–7282.
   PubMed Web of Science ®Google Scholar
• Bralet MP, Pichard V, Ferry N. Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats. Hepatology (Baltimore, Md). 2002;36:623–630.
   PubMed Web of Science ®Google Scholar
• Zahran AM, Aly SS, Rayan A, et al. Survival outcomes of CD34(+)CD38(–)LSCs and their expression of CD123 in adult AML patients. Oncotarget. 2018;9:34056–34065.
   PubMedGoogle Scholar
• Zahran AM, Rayan A, Fakhry H, et al. Pretreatment detection of circulating and tissue CD133(+) CD44(+) cancer stem cells as a prognostic factor affecting the outcomes in Egyptian patients with colorectal cancer. Cancer Manag Res. 2019;11:1237–1248.
   PubMed Web of Science ®Google Scholar
• Tsai KS, Yang SH, Lei YP, et al. Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology. 2011;141:1046–1056.
   PubMed Web of Science ®Google Scholar
• Lugli A, Iezzi G, Hostettler I, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer. 2010;103:382–390.
   PubMed Web of Science ®Google Scholar
• Pang RW, Poon RT. Cancer stem cell as a potential therapeutic target in hepatocellular carcinoma. Curr Cancer Drug Targets. 2012;112:1081–1094.
   Google Scholar
• Otto W, Krol M, Maciaszczyk M, et al. Levels and values of circulating hematopoietic and endothelial progenitor cells in patients with hepatocellular carcinoma. J Liver. 2014;03:167.
   Google Scholar
• Zahran AM, Aly SS, Altayeb HA, et al. Circulating endothelial cells and their progenitors in acute myeloid leukemia. Oncol Lett. 2016;12:1965–1970.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Hao X, Yan M, et al. Cancer stem/progenitor cells are highly enriched in CD133 + CD44+ population in hepatocellular carcinoma. Int J Cancer. 2010;126:2067–2078.
   PubMed Web of Science ®Google Scholar
• Mansour AH, Elkhoda TR, Ayyad RS, et al. Regulation of cancer stem cell marker (CD133) by transforming growth factor beta in hepatocellular carcinoma. Int J Cancer Res. 2014;10:65–73.
   Google Scholar
• Song W, Li H, Tao K, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008;62:1212–1218.
   PubMed Web of Science ®Google Scholar
• Yeh CT, Kuo CJ, Lai MW, et al. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer. 2009;9:324.
   PubMed Web of Science ®Google Scholar
• Sasaki A, Kamiyama T, Yokoo H, et al. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep. 2010;24:537–546.
   PubMed Web of Science ®Google Scholar
• Hirohashi K, Yamamoto T, Uenishi T, et al. CD44 and VEGF expression in extrahepatic metastasis of human hepatocellular carcinoma. Hepato-gastroenterology. 2004;51:1121–1123.
   PubMed Web of Science ®Google Scholar
• Zahran AM, Nafady-Hego H, Mansor SG, et al. Increased frequency and FOXP3 expression of human CD8+ CD25High + lymphocytes and its relation to CD4 T regulatory cells in patients with hepatocellular carcinoma. Hum Immunol. 2019;80:510.
   PubMed Web of Science ®Google Scholar
• Zahran AM, Zahran ZAM, El-Badawy O, et al. Prognostic impact of toll-like receptors 2 and 4 expression on monocytes in Egyptian patients with hepatocellular carcinoma. Immunol Res. 2019.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md). 2011;53:1020–1022.
   PubMed Web of Science ®Google Scholar
• Cancer EAFTSOTLEOFRATO. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
   PubMed Web of Science ®Google Scholar
• Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ: Can Med Assoc J = journal de l'Association medicale canadienne. 2005;172:367–379.
   PubMed Web of Science ®Google Scholar
• Yang XR, Xu Y, Yu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010;59:953–962.
   PubMed Web of Science ®Google Scholar
• Liu R, Shen Y, Nan K, et al. Association between expression of cancer stem cell markers and poor differentiation of hepatocellular carcinoma: a meta-analysis (PRISMA). Medicine. 2015;94:e1306.
   PubMed Web of Science ®Google Scholar
• Vilchez V, Zaytseva Y, Stewart R, et al. Liver cancer stem cell markers (CD133+/CD44+) are strongly associated with moderate to poorly differentiated hepatocellular carcinoma in patients undergoing transplantation.: Abstract# A387. Transplantation. 2014;98:697.
   PubMed Web of Science ®Google Scholar
• Romano M, De Francesco F, Pirozzi G, et al. Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. Oncoscience. 2015;2:443–456.
   PubMedGoogle Scholar
• Guo Z, Li LQ, Jiang JH, et al. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. World J Gastroenterol. 2014;20:2098–2106.
   PubMed Web of Science ®Google Scholar
• Chan AW, Tong JH, Chan SL, et al. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology. 2014;64:935–950.
   PubMed Web of Science ®Google Scholar